AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

AbCellera Biologics reports Q3 loss but poised for clinical advancements

AbCellera Biologics is navigating its transition to a clinical stage biotech with promising programs and a strong financial position.
While facing challenges in managing R&D expenses and achieving profitability, the company's strategic moves and preparedness for clinical trials bode well for future growth.
Opportunities lie in further investments in development, advancing novel therapies, and leveraging its financial strength to capitalize on emerging opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech is now down roughly 56% across 2021's trading.

Why AbCellera Biologics Stock Sank 21.6% in October

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for COVID-19

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs. In September, AbCellera's current antibody therapy was put back into use after an FDA pause, giving the company back a key revenue source

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

Why AbCellera Biologics Stock Jumped 19.4% Last Month

AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.

AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies

VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) increased by over 16% pre-market. This is why it happened.

ABCL Stock: Why It Increased Today

Eli Lilly

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SARS-CoV-2 infection.  Bamlanivimab emerged from the collaboration between Eli Lilly And Co (NYSE: LLY) and AbCellera Biologics Inc (NASDAQ: ABCL).

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

The company's drug-development technology is starting to attract attention.

Why AbCellera Biologics Stock Jumped 7% on Wednesday

Moderna

AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

VANCOUVER, British Columbia & BOSTON--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.

Here's Why AbCellera Biologics Stock Gained 10.6% Last Month

AbCellera reported Q2 results on 08/12/21 which were well received by the market, sending shares up 15%. A remark by the CEO in the conference call, however, has me quite concerned. The company since IPO has indicated that royalties negotiated are between single digits and low double digits, allowing the impression to set that the average is somewhere in the 8-12% range.

AbCellera Biologics: I Was Wrong

The biopharma company's second quarter was better than expected. The future looks pretty bright, too.

Why AbCellera Biologics Stock Was Up More Than 17% on Friday

AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results

AbCellera Reports Q2 2021 Business Results

ACADIA Pharma

Amicus Therapeutics

Sarepta Therapeutics

TG Therapeutics

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

First, AbCellera is a Life Sciences Tools and Services play, not a biotech or pharmaceutical.

AbCellera Biologics: A Buy At Current Prices

CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration agreement for the discovery and development of therapeutic antibodies. The collaboration will leverage AbCellera's AI-powered antibody discovery technology to search and

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

News for AbCellera Biologics Stock (ABCL)